OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020
OrphoMed, Inc., a clinical-stage biopharmaceutical company, today announced the presentation at Digestive Disease Week (DDW) of Phase 1 data for its lead candidate ORP-101, being developed for the treatment of irritable bowel syndrome with diarrhea.
OrphoMed, Inc., a clinical-stage biopharmaceutical company, today announced the presentation at Digestive Disease Week® (DDW) of Phase 1 data for its lead candidate ORP-101, being developed for the treatment of irritable bowel syndrome with diarrhea.
Anthony J. Lembo, M.D., Director of the GI Motility and Functional Bowel Disorders Program at Beth Israel Deaconess Medical Center and Associate Professor at Harvard Medical School, will present the results on Monday, May 4, 12:30 – 1:30 p.m. CST, at Chicago’s McCormick Place Convention Center, South Hall A, Level 3.
“ORP-101 is uniquely designed to simultaneously modulate gastrointestinal motility and attenuate abdominal pain by interacting only with peripheral mu and kappa opioid receptors without central nervous system opioid side effects and complications,” said Dr. Lembo, who is the Chair of OrphoMed’s Scientific Advisory Board. “I am excited to lead the clinical investigation of ORP-101 in IBS-D patients, and I look forward to presenting the results of the Phase 1 single and multiple ascending dose safety, tolerability, and pharmacokinetic studies during DDW 2020.”
About ORP-101
ORP-101 is a new chemical entity designed to have partial mu agonist and full kappa antagonist effects on peripheral opioid receptors.
Key highlights:
- FDA Fast-track for IBS-D
- Enrolling investigators and patients for Phase 2 study http://prevailibsdstudy.com/.
About OrphoMed, Inc.
OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics. Leveraging its proprietary dimer platform technology engineered by founder Nikhilesh Singh, Ph.D., OrphoMed is advancing ORP-101 and a pipeline of additional dimer conjugates. In May 2017, OrphoMed completed a $39 million Series A financing with New Enterprise Associates, Takeda Ventures, Pappas Capital and Relativity Healthcare. For more information please visit www.orphomed.com.
Forward-Looking Statements
This press release contains “forward-looking statements,” which reflect our current views and expectations with respect to future outcomes or events. When used in this press release, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Because these statements are based on current estimates and assumptions, they are inherently subject to risks that could cause the actual outcomes to differ materially from what we currently expect. These forward-looking statements are subject to numerous risks and uncertainties, including, among others, the facts that we are substantially dependent on our ability to successfully develop and commercialize our products; the commercial adoption of our products and any other product candidates we develop will depend on the degree of their market acceptance; we have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable; and we have never generated any revenue and may never be profitable. Forward-looking statements in this presentation apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005113/en/